Pharmaceutical compositions comprising monoterpenes
The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.
1. A process for purifying (S)-perillyl alcohol comprising the steps of:
(a) derivatizing a mixture comprising (S)-perillyl alcohol to form a perillyl alcohol derivative;
(b) crystallizing the perillyl alcohol derivative;
(c) separating the perillyl alcohol derivative crystals from the mixture;
(d) releasing the (S)-perillyl alcohol from the separated perillyl alcohol derivative from step (c); and,
(e) isolating the (S)-perillyl alcohol from step (d),
wherein the isolated (S)-perillyl alcohol has a purity of greater than about 98.5% (w/w).
2. The process of claim 1 , wherein the perillyl alcohol derivative is a perillyl alcohol ester.
3. The process of claim 2 , wherein the ester is a benzoate ester.
4. The process of claim 3 , wherein the benzoate ester is 3,5-dinitrobenzoate ester.
5. The process of claim 1 , wherein the isolated (S)-perillyl alcohol has a purity of greater than about 99.0% (w/w).
6. The process of claim 5 , wherein the isolated (S)-perillyl alcohol has a purity of greater than about 99.5% (w/w).
7. The process of claim 1 , wherein the mixture further comprises natural-product-derived or other impurities.